Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness

AIBL Research Group

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Introduction High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.

Original languageEnglish
Pages (from-to)156-164
Number of pages9
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume8
DOIs
StatePublished - Jan 1 2017

Keywords

  • Alzheimer disease
  • Amyloid
  • Cognitive aging
  • Memory
  • Normal aging

Fingerprint Dive into the research topics of 'Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness'. Together they form a unique fingerprint.

  • Cite this